DK0972517T3 - Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer - Google Patents

Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer

Info

Publication number
DK0972517T3
DK0972517T3 DK99118533T DK99118533T DK0972517T3 DK 0972517 T3 DK0972517 T3 DK 0972517T3 DK 99118533 T DK99118533 T DK 99118533T DK 99118533 T DK99118533 T DK 99118533T DK 0972517 T3 DK0972517 T3 DK 0972517T3
Authority
DK
Denmark
Prior art keywords
tumors
treatment
administering
drug
manufacture
Prior art date
Application number
DK99118533T
Other languages
English (en)
Inventor
Martin J Brown
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK0972517T3 publication Critical patent/DK0972517T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99118533T 1993-09-22 1994-09-19 Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer DK0972517T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/125,609 US5484612A (en) 1993-09-22 1993-09-22 Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
EP94202693A EP0649658B1 (en) 1993-09-22 1994-09-19 Use of 1,2,4-benzotriazine oxides for the manufacture of a medicament for the treatment of tumors

Publications (1)

Publication Number Publication Date
DK0972517T3 true DK0972517T3 (da) 2004-11-08

Family

ID=22420569

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94202693T DK0649658T3 (da) 1993-09-22 1994-09-19 Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer
DK99118533T DK0972517T3 (da) 1993-09-22 1994-09-19 Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK94202693T DK0649658T3 (da) 1993-09-22 1994-09-19 Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer

Country Status (22)

Country Link
US (4) US5484612A (da)
EP (2) EP0972517B1 (da)
JP (1) JPH07215882A (da)
KR (1) KR100383402B1 (da)
AT (2) ATE193827T1 (da)
AU (1) AU690132B2 (da)
CA (1) CA2132578C (da)
CZ (1) CZ289742B6 (da)
DE (2) DE69424915T2 (da)
DK (2) DK0649658T3 (da)
ES (2) ES2147567T3 (da)
GR (1) GR3034360T3 (da)
HU (1) HUT71119A (da)
IL (1) IL111025A (da)
MY (1) MY112405A (da)
NO (1) NO943524L (da)
NZ (2) NZ264502A (da)
PT (2) PT972517E (da)
RU (1) RU2148406C1 (da)
SG (1) SG52568A1 (da)
SK (1) SK282178B6 (da)
UA (1) UA49787C2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
EP1014990B1 (en) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
CA2309919A1 (en) * 1997-11-14 1999-05-27 The General Hospital Corporation Treatment of hematologic disorders
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6819761B1 (en) * 1999-09-16 2004-11-16 Silicon Laboratories, Inc. Programmable constant current “off hook” circuit
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
EP1254122B1 (de) 1999-12-21 2008-09-17 UFZ-UMWELTFORSCHUNGSZENTRUM Leipzig-Halle GmbH Neue 3-substituierte 1,2,4-benzotriazine, verfahren zu ihrer herstellung und ihre verwendung zur behandlung und prophylaxe von tumorerkrankungen
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
RU2166945C1 (ru) * 2000-08-08 2001-05-20 Ефимова Лариса Степановна Радиосенсибилизирующее вещество для лечения онкологических заболеваний
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
AT412703B (de) 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
WO2005082867A1 (en) * 2004-03-01 2005-09-09 Auckland Uniservices Limited Novel 1,2,4-benzotriazine-1,4-dioxides
DK1866292T3 (da) 2005-03-31 2011-05-09 Auckland Uniservices Ltd Tricykliske 1,2,4-triazinoxider og sammensætninger deraf til terapeutisk anvendelse i cancerbehandlinger
WO2007041546A2 (en) * 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Method for selectively depleting hypoxic cells
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
EP2244760B8 (en) * 2008-01-28 2022-07-20 Implantica Patent Ltd. An implantable drainage device
US8591921B2 (en) 2008-04-10 2013-11-26 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
US9316632B2 (en) * 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
AT511159A1 (de) 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
JP2015500295A (ja) * 2011-12-07 2015-01-05 エスアールアイ インターナショナルSRI International ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN114340740A (zh) * 2019-07-01 2022-04-12 库拉森疗法公司 β肾上腺素能激动剂及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides

Also Published As

Publication number Publication date
CZ232694A3 (en) 1995-09-13
ES2147567T3 (es) 2000-09-16
AU690132B2 (en) 1998-04-23
PT972517E (pt) 2004-11-30
US5484612A (en) 1996-01-16
PT649658E (pt) 2000-12-29
SK114894A3 (en) 1995-11-08
CZ289742B6 (cs) 2002-03-13
KR100383402B1 (ko) 2003-09-22
MY112405A (en) 2001-06-30
IL111025A (en) 2006-04-10
DE69424915T2 (de) 2001-01-18
EP0972517B1 (en) 2004-07-07
NO943524D0 (no) 1994-09-22
DE69424915D1 (de) 2000-07-20
NO943524L (no) 1995-03-23
ATE270553T1 (de) 2004-07-15
NZ264502A (en) 1997-06-24
US6121263A (en) 2000-09-19
US6277835B1 (en) 2001-08-21
EP0972517A2 (en) 2000-01-19
HU9402726D0 (en) 1994-12-28
UA49787C2 (uk) 2002-10-15
ES2224517T3 (es) 2005-03-01
AU7411794A (en) 1995-04-06
US5670502A (en) 1997-09-23
EP0649658A1 (en) 1995-04-26
SG52568A1 (en) 1998-09-28
DE69433889D1 (de) 2004-08-12
RU2148406C1 (ru) 2000-05-10
KR950007853A (ko) 1995-04-15
JPH07215882A (ja) 1995-08-15
EP0649658B1 (en) 2000-06-14
ATE193827T1 (de) 2000-06-15
HUT71119A (en) 1995-11-28
DK0649658T3 (da) 2000-09-11
GR3034360T3 (en) 2000-12-29
CA2132578C (en) 1998-10-13
DE69433889T2 (de) 2005-06-30
EP0972517A3 (en) 2000-01-26
NZ299690A (en) 1997-11-24
RU94034104A (ru) 1996-11-10
IL111025A0 (en) 1994-11-28
SK282178B6 (sk) 2001-11-06
CA2132578A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
DK0972517T3 (da) Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer
EA199900137A1 (ru) Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
TW229156B (da)
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
ATE28641T1 (de) Pharmazeutische praeparate, (+)-cyanidan-3-olderivate enthaltend, deren verwendung, substituierte (+)-cyanidan-3-ol derivate und verfahren zu deren herstellung.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ES2134778T3 (es) Bistriazenos como agentes quimioterapeuticos.
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme